In September 2004, Bionomics granted a license to Massachusetts-based Athena Diagnostics to market Bionomics' Severe Myoclonic Epilepsy of Infancy (SMEI) diagnostic test in North America and Japan. Athena is a specialist in diagnostic testing for neurological disorders and provides the gene-based SMEI test to over 5,000 neurologists.

Bionomics' diagnostic method is the first genetic test available to clinicians to allow them to distinguish SMEI from less serious forms of epilepsy. Early diagnosis should reduce the cost associated with current diagnostic procedures for SMEI and will enable doctors to implement appropriate treatment strategies, which it is hoped will reduce the high (18%) mortality rate associated with SMEI. Around 240,000 children in the United States may be candidates for the SMEI test.

For more information about Athena Diagnostics, visit